Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will ...
Finding new ways in the approach to colorectal cancer is therefore fundamental. And there is no shortage of good news. Italy is the first country in Europe to guarantee, through the National Health ...
Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...
A recent national survey reveals that many Americans remain unaware of the health risks associated with processed meat, even as colorectal cancer rates in younger adults continue to rise. The findings ...
aDepartment of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA bDepartment of Obstetrics, Gynecology, and Women's Health, University of ...
aDepartment of Mathematics and Statistics University of Helsinki, Helsinki, Finland bDepartment of Medical and Clinical Genetics University of Helsinki, Helsinki, Finland ...
The FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for adult patients with metastatic colorectal cancer (mCRC) harboring a BRAF ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved encorafenib plus cetuximab and fluorouracil-based chemotherapy for adults with BRAF ...
The FDA has granted traditional approval to encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, Eli Lilly) and fluorouracil-based chemotherapy for treatment of adults with ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results